UPDATE: Jefferies Assumes Novavax (NVAX) at Buy; Sees ~$4.6B in 2022 COVID-19 Vaccine Sales
Tweet Send to a Friend
(Updated - February 22, 2022 7:44 AM EST)Jefferies analyst Roger Song assumes coverage on Novavax (NASDAQ: NVAX) with a Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
